Data Demonstrating Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy in Detecting Lung Cancer Mutations Presented at UCSD Moores Cancer Center Translational Oncology Symposium
"The results of this study further demonstrate the ability of
"The ability of the Target-Selector™ assay to detect rare genetic events from blood has great utility when applied to patients with lung cancer, where it is often challenging to obtain a tissue sample," said
Determining the presence of circulating tumor DNA (ctDNA) in blood, which is indicative of the presence of solid tumors, is the goal of assays known as "liquid biopsies." The use of a liquid biopsy is proving useful for monitoring a patient's tumor burden and for guiding the personalized treatment of patients with cancer based on the presence of biomarkers associated with solid tumors. Historically, solid tumor tissue obtained from surgical biopsies has been used routinely to detect the presence of key genomic biomarkers that can aid in the detection of cancer and in treatment decision-making. The ability to detect these same biomarkers based on material shed from the tumor into the blood provides an alternative for physicians where a solid tumor biopsy is difficult or impractical to obtain, or poses a high risk to the patient.
About
Forward-Looking Statements
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the detection and treatment of cancer, our ability to demonstrate the
performance and clinical utility of our liquid biopsy platform, our plans to introduce
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/data-demonstrating-extremely-high-sensitivity-of-biocepts-blood-based-liquid-biopsy-in-detecting-lung-cancer-mutations-presented-at-ucsd-moores-cancer-center-translational-oncology-symposium-300226766.html
SOURCE
News Provided by Acquire Media